Elisabeth Pharmacon Research and Development Center (Q9634): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: financed by (P890): Directorate-General for Regional and Urban Policy (Q8361), Removing unnecessary financed by statement) |
(Changed an Item: Change because item Q214251 was merged with Q4868) |
||
| Property / contained in NUTS | Property / contained in NUTS | ||
Revision as of 19:34, 27 December 2020
Project Q9634 in Czech Republic
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Elisabeth Pharmacon Research and Development Center |
Project Q9634 in Czech Republic |
Statements
6,742,616.0 Czech koruna
0 references
13,485,232.0 Czech koruna
0 references
50 percent
0 references
26 June 2015
0 references
25 June 2018
0 references
25 June 2018
0 references
ELISABETH PHARMACON, spol. s r.o.
0 references
49°11'55.75"N, 16°38'29.22"E
0 references
61500
0 references
Projekt je zaměřen na rozvoj stávajícího výzkumného, vývojového a inovačního centra společnosti, které slouží k vývoji inovativních postupů lékařské DNA diagnostiky infekčních a geneticky podmíněných chorob. Cílem projektu je posílení současných vývojových a inovačních kapacit, zaměřené na nejnovější trendy v našem oboru včetně metod sekvenování nové generace. Projekt se soustřeďuje na vývoj inovativních diagnostických postupů a souprav. (Czech)
0 references
The project is focused on the development of the existing research, development and innovation centre of the company, which is used to develop innovative procedures of medical DNA diagnostics of infectious and genetically conditioned diseases. The aim of the project is to strengthen current development and innovation capacities, focusing on the latest trends in our field, including new generation sequencing methods. The project focuses on the development of innovative diagnostic procedures and sets. (English)
22 October 2020
0 references
Identifiers
CZ.01.1.02/0.0/0.0/15_002/0000699
0 references